1. Sharma M. Combination therapy for dyslipidemia. Curr Opin Cardiol 2011; 26(5):420-3.
2. Mashimo Y., Teramoto T. Principles pharmacotherapy for dyslipidemia associated with metabolic syndrome. Nihon Rinsho. 2011;69:601-6.
3. Kopin L, Lowenstein C. In the clinic: Dyslipidemia. Ann Intern Med 2010; 153(3): ITC21.
4. Paraskevas KI, Karatzas G, Pantopoulou A, Iliopoulos DG, Perrea D. Targeting dyslipidemia in the metabolic syndrome: an update. Curr Vasc Pharmacol 2010; 8: 450-63.
5. Raal FJ. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord 2009; 7: 83-88.
6. Iughetti L, Bruzzi P, Predieri B. Evaluation and management of hyperlipidemia in children and adolescents. Curr Opin Pediatr 2010; 22: 485-93.
7. Chanoine P, Spector ND. Hyperlipidemia, eating disorders, and smoking cessation. Curr Opin Pediatr 2008; 20: 734-9.
8. Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg Med Chem 2007; 15: 4674-99.
9. Fonseca VA. The metabolic syndrome, hyperlipidemia, and insulin resistance. Clin Cornerstone 2005; 7: 61-72.
10. Nobukuni Y, Higashikawa F, Miyagawa K, Eboshida A. Hyperlipidemia: complex pathophysiology caused by multiple genetic and environmental factors--in considering the approaches to preventive medicine. Nihon Eiseigaku Zasshi 2005; 60: 426-41.
11. Eaton CB. Hyperlipidemia. Prim Care. 2005; 32: 1027-55.
12. Seishima M. Guideline for hyperlipidemia. Rinsho Byori 2003; 51: 576-80.
13. Kanani PM, Sperling MA. Hyperlipidemia in adolescents. Adolesc Med 2002; 13: 37-52.
14. Farnier M. Safety review of combination drugs for hyperlipidemia. Expert Opin Drug Saf 2011; 10: 363-71.
15. Hasani-Ranjbar S, Nayebi N, Moradi L, Mehri A, Larijani B, Abdollahi M. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Curr Pharm Des 2010; 16: 2935-47.
16. Reindl EK, Wright BM, Wargo KA. Alternate-day statin therapy for the treatment of hyperlipidemia. Ann Pharmacother 2010; 44: 1459-70.
17. Paras C, Hussain MM, Rosenson RS. Emerging drugs for hyperlipidemia. Expert Opin Emerg Drugs 2010; 15: 433-51.
18. Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. J Clin Endocrinol Metab 2003; 88: 2445-61.
19. Henley E, Chang L, Hollander S. Treatment of hyperlipidemia. J Fam Pract 2002; 51: 370-6.
20. Boldyrev AA, Stvolinsky SL, Fedorova TN, Suslina ZA. Crnosine as a natural antioxidant and geroprotector from molecular mechanisms to clinical trials. Rejuvenation Res 2010; 13: 156-8.
21. Hipkiss AR. Carnosine and its possible roles in nutrition and health. Adv Food Nutr Res 2009; 57: 87-154.
22. Boldyrev AA, Stvolinskiĭ SL, Fedorova TN. Carnosine: endogenous physiological corrector of antioxidative system activity. Usp Fiziol Nauk 2007; 38: 57-71.
23. Zieba R. Carnosine--biological activity and perspectives in pharmacotherapy. Wiad Lek 2007; 60: 73-9.
24. Volkov OV. Biological role of carnosine and its use in ophthalmology (mini-review. Biomed Khim 2005; 51: 481-4.
25.Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosine-related antioxidants: a review. Curr Med Chem 2005; 12: 2293-315
26. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ 2005; 18: 12.
27. Ozdogan K, Taskın E, Dursun N. Protective effect of carnosine on adriamycin-induced oxidative heart damage in rats. Anadolu Kardiyol Derg. 2011; 11: 3-10.
28. Aydogan S, Yapislar H, Artis S, Aydogan B. Impaired erythrocytes deformability in H(2)O(2)-induced oxidative stress: protective effect of L-carnosine. Clin Hemorheol Microcirc 2008; 39: 93-8.
29. Kurata H, Fujii T, Tsutsui H, Katayama T, Ohkita M, Takaoka M, et al. Renoprotective effects of l-carnosine on ischemia/reperfusion-induced renal injury in rats. J Pharmacol Exp Ther 2006; 319: 640-7.
30. Peters V, Schmitt CP, Zschocke J, Gross ML, Brismar K, Forsberg E. Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. Amino Acids 2012; 42(6):2411-6.
31. Duchemin S, Belanger E, Wu R, Ferland G, Girouard H. Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice. Physiol Behav 2012; 12: 330-7.
)